In this article, Dr. Gerardo Villarreal Berain and Dr. Rebeca Castillo Del Ángel present a structured scientific review comparing the clinical outcomes of semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in the management of metabolic and cardiovascular conditions. Both therapies have revolutionized the treatment landscape for obesity and type 2 diabetes. However, emerging evidence suggests their benefits … Sigue leyendo Comparative Impact of Semaglutide and Tirzepatide on Cardiometabolic Health: A Review of the Evidence. April 14, 2025.